Aptose Biosciences Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.aptose.com

Market Cap $3.29M
Debt $NaN
Cash $7.96M
EV $NaN
FCF -$37.16M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-35.8M
FCF	-$37.16M
Equity	-$9.13M
Growth Stability	1
PE	-0.09
PB	-0.36
P/FCF	-0.09
Price/Cash	2.42
Equity CAGR	3%
Earnings Growth YoY	-39%
Earnings Growth QoQ	-4%
Equity CAGR 5Y	-33%

Equity CAGR 3Y	-50%
Market Cap	$3.29M
Revenue	$0.00
Assets	$10.93M
Cash	$7.96M
Shares Outstanding	16.11M
Working Capital	477K
Current Ratio	1.05
Shares Growth 3y	11%
Equity Growth QoQ	320%
Equity Growth YoY	-217%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.

SEC Filings

Direct access to Aptose Biosciences Inc. (APTO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Aptose Biosciences Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aptose Biosciences Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Aptose Biosciences Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aptose Biosciences Inc..

Years

Calculation mode

= -$372M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$372M
DCF		-$34M	-$31M	-$28M	-$25M	-$23M	-$21M	-$19M	-$17M	-$16M	-$14M	-$143M
Value	-$372M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-	-	-	-	-	-
ROA	-	-	-	-	-	-	-	-	-	-
ROE	-	-	-114%	-205%	-28%	-46%	-88%	-111%	2K%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-	-	-
Earnings YoY growth	-	27%	-37%	148%	-9%	110%	18%	-36%	22%	-
Equity YoY growth	-	-	39%	38%	567%	27%	-38%	-49%	-108%	-33%
FCF YoY growth	-	-	-	130%	-8%	57%	28%	-26%	38%	-